Incyte Announces Updated Presentation Time for Upcoming Investor Conference

11/26/24 4:10:00 PM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $INCY alert in real time by email

Incyte (NASDAQ:INCY) announced today that it will now present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241126113474/en/

Get the next $INCY alert in real time by email

Date	Price Target	Rating	Analyst
6/16/2025	$107.00	Hold → Buy	Stifel
3/18/2025		Buy → Neutral	Guggenheim
3/18/2025		Outperform → Mkt Perform	William Blair
12/17/2024	$77.00	Neutral	UBS
10/29/2024	$68.00 → $90.00	Neutral → Buy	BofA Securities
10/1/2024	$84.00	Outperform	Wolfe Research
9/18/2024	$83.00 → $74.00	Buy → Hold	Truist
7/2/2024	$52.00 → $48.00	Market Perform → Underperform	BMO Capital Markets

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Chat with this insight

Recent Analyst Ratings for
$INCY

$INCY
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for JAKAFI issued to INCYTE CORP

FDA Approval for JAKAFI issued to INCYTE CORP

FDA Approval for OPZELURA issued to INCYTE CORP

$INCY
Leadership Updates

Live Leadership Updates

Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

Incyte Names New Member to Its Board of Directors

Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

$INCY
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Brawley Otis W was granted 2,518 shares, increasing direct ownership by 29% to 11,252 units (SEC Form 4)

Director Fouse Jacqualyn A was granted 2,518 shares, increasing direct ownership by 15% to 19,326 units (SEC Form 4)

Director Bienaime Jean Jacques was granted 2,518 shares, increasing direct ownership by 14% to 20,841 units (SEC Form 4)

$INCY
SEC Filings

Incyte Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Incyte Corp. filed SEC Form 8-K: Other Events

SEC Form DEFA14A filed by Incyte Corp.

$INCY
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Incyte upgraded by Stifel with a new price target

Incyte downgraded by Guggenheim

Incyte downgraded by William Blair

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Chat with this insight

Recent Analyst Ratings for $INCY

$INCY FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for JAKAFI issued to INCYTE CORP

FDA Approval for JAKAFI issued to INCYTE CORP

FDA Approval for OPZELURA issued to INCYTE CORP

$INCY Leadership Updates

Live Leadership Updates

Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

Incyte Names New Member to Its Board of Directors

Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

$INCY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Brawley Otis W was granted 2,518 shares, increasing direct ownership by 29% to 11,252 units (SEC Form 4)

Director Fouse Jacqualyn A was granted 2,518 shares, increasing direct ownership by 15% to 19,326 units (SEC Form 4)

Director Bienaime Jean Jacques was granted 2,518 shares, increasing direct ownership by 14% to 20,841 units (SEC Form 4)

$INCY SEC Filings

Incyte Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Incyte Corp. filed SEC Form 8-K: Other Events

SEC Form DEFA14A filed by Incyte Corp.

$INCY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Incyte upgraded by Stifel with a new price target

Incyte downgraded by Guggenheim

Incyte downgraded by William Blair

Recent Analyst Ratings for
$INCY

$INCY
FDA approvals

$INCY
Leadership Updates

$INCY
Insider Trading

$INCY
SEC Filings

$INCY
Analyst Ratings